Trials / Unknown
UnknownNCT02991235
Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease
Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Bioiberica · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A 6-month randomized, double-blind and placebo-controlled, followed by a 6-month open label extension study.
Detailed description
Men and women from 60 to 85 years old with diagnosis of mild severity Alzheimer's disease, according to the diagnostic criteria established by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | PRJ212 | 6 capsules of study product will be taken daily and orally. |
| DIETARY_SUPPLEMENT | Placebo | 6 capsules of study product will be taken daily and orally. |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2018-07-01
- Completion
- 2018-12-01
- First posted
- 2016-12-13
- Last updated
- 2018-01-19
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02991235. Inclusion in this directory is not an endorsement.